HBV-TCR T Cell Therapy is under clinical development by Lion TCR and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HBV-TCR T Cell Therapy’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HBV-TCR T Cell Therapy overview

The therapeutic candidate is under development for the treatment of chronic hepatitis B virus infections. It comprises of T cells transfected with mRNA encoding hepatitis-B virus (HBV) antigen specific T cell receptor (TCR). It is administered through intravenous route.

Lion TCR overview

Lion TCR., is a clinical-stage biotechnology company that develops cell therapy for cancers and life-threatening infectious diseases. The company is headquartered in Singapore.

For a complete picture of HBV-TCR T Cell Therapy’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.